The availability of human cell and tissue models is transforming preclinical drug development. Applications range from early stages of drug development to advanced individualized phenotypic screens. The promise is that clinical outcome as to safety and efficacy can be predicted early to expedite and de-risk drug development.
- Cyganek L, Tiburcy M, Sekeres K, Gerstenberg K, Bohnenberger H, Lenz C, Henze S, Stauske M, Salinas G, Zimmermann WH, Hasenfuss G, Guan K (2018) Deep phenotyping of human induced pluripotent stem cell-derived atrial and ventricular cardiomyocytes. JCI Insight. 3.
- Tiburcy M, Meyer T, Soong PL, Zimmermann WH (2014) Collagen-based engineered heart muscle. Methods Mol Biol. 1181:167-76.
- Tiburcy M, Hudson JE, Balfanz P, Schlick S, Meyer T, Chang Liao ML, Levent E, Raad F, Zeidler S, Wingender E, Riegler J, Wang M, Gold JD, Kehat I, Wettwer E, Ravens U, Dierickx P, van Laake LW, Goumans MJ, Khadjeh S, Toischer K, Hasenfuss G, Couture LA, Unger A, Linke WA, Araki T, Neel B, Keller G, Gepstein L, Wu JC, Zimmermann WH (2017) Defined Engineered Human Myocardium With Advanced Maturation for Applications in Heart Failure Modeling and Repair. Circulation. 135:1832-1847.